Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose escalation and expansion study of PF-07062119 in advanced gastrointestinal tumors
jRCT2080225145Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of PF-07062119 in colorectal adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Pfizer. Primary endpoints: Safety and tolerability of PF-07062119 and Pharmacokinetics of PF-07062119. Started Mar 2020; status: completed.
02
Drugs
PF-07062119
03
Conditions
colorectal adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2080225145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225145.